第一作者机构:[1]Univ Elect Sci & Technol China, Sch Med, Sichuan Canc Ctr, Sichuan Canc Hosp & Inst, Chengdu, Peoples R China[2]Shandong Acad Med Sci, Shandong Canc Hosp, Dept Med Oncol, Jinan 250117, Peoples R China[3]Univ Elect Sci & Technol China, Sch Med, Sichuan Canc Ctr, Dept Pathol,Sichuan Canc Hosp & Inst, Chengdu, Sichuan, Peoples R China
推荐引用方式(GB/T 7714):
Chen Yungchang,Li Xiaoqian,Man Yuxin,et al.Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mutated metastatic colorectal cancer[J].JOURNAL OF CLINICAL ONCOLOGY.2023,41:156-156.doi:10.1200/JCO.2023.41.4_suppl.156.
APA:
Chen, Yungchang,Li, Xiaoqian,Man Yuxin,Hu, Hai,Wang, Liyang...&Lin, Tongyu.(2023).Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mutated metastatic colorectal cancer.JOURNAL OF CLINICAL ONCOLOGY,41,
MLA:
Chen, Yungchang,et al."Phase Ib study of dabrafenib, trametinib, irinotecan and cetuximab in BRAF V600E-mutated metastatic colorectal cancer".JOURNAL OF CLINICAL ONCOLOGY 41.(2023):156-156